目的 探讨司美格鲁肽不良反应的发生规律和临床表现特点，为临床安全、合理用药提供参考。方法 检索中国知网、万方、维普、PubMed、Web of Science、Embase数据库，收集司美格鲁肽所致不良反应案例报道，进行统计分析。结果 共纳入文献21篇，涉及患者27例，女性17例（62.96%），男性10例（37.04%），平均年龄（52.19±17.05）岁。司美格鲁肽主要用于糖尿病和减重，不良反应多发生在用药2个月内（19例，70.37%），主要累及胃肠系统、免疫系统、肝胆系统、肾脏及泌尿系统等。27例患者经停药和对症治疗后，25例好转，2例无明显改善。结论 临床医生、药师应加强对司美格鲁肽相关不良反应的认识和监测，及时诊断与治疗，确保用药安全。

Objective To investigate the regularity and clinical characteristics of adverse drug reactions of semaglutide in order to provide reference for clinical medication. Methods Case reports of the adverse drug reactions induced by semaglutide were retrieved from the databases of CNKI, Wanfang, VIP, PubMed, Web of Science and Embase, etc. Results A total of 27 cases were reported in 21 papers, including 10 males (37.04%) and 17 females(62.96%). The mean age of the patients was (52.19 ±17.05) years old. Semaglutide was mainly used for diabetes mellitus and weight loss, and adverse drug reactions occurred mostly within 2 months (19 cases, 70.37%), mainly involving gastrointestinal system, immune system, hepatobiliary system, kidney and urinary system, etc. After drug withdrawal and symptomatic treatment, 25 patients improved and 2 patients had no obvious improvement. Conclusion It is necessary to strengthen the understanding and monitoring the adverse drug reactions induced by semaglutide, and timely perform diagnosis and treatment of the adverse drug reactions to ensure medication safety.

R977

广东省中医药局科研项目（20222154）